Love Pharma Inc. an international sexual health, wellness, and psychedelics company, in partnership with a US based pharmaceutical company, is developing a muco-adhesive sublingual strip for the delivery of psilocybin.Following the 2018 breakthrough designation by the FDA for psilocybin, the psychoactive chemical in mushrooms, companies have been fast-tracking its use in drug trials in the mental healthcare field, ...

Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) an international sexual health, wellness, and psychedelics company, in partnership with a US based pharmaceutical company, is developing a muco-adhesive sublingual strip for the delivery of psilocybin.

Following the 2018 breakthrough designation by the FDA for psilocybin, the psychoactive chemical in mushrooms, companies have been fast-tracking its use in drug trials in the mental healthcare field, with prominent medical institutions and research facilities in the UK and US conducting studies and trials to determine the efficacy of psilocybin in treating a number of debilitating conditions.



Cannot view this video? Visit:
http://www.investmentpitch.com/video/1_yrhj53be/LOVE-Pharma-announces-development-of-muco-adhesive-strip-technology-for-the-delivery-of-psilocybin.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Love Pharma" in the search box.

A recent Phase II study at Imperial College London as reported in the New England Journal of Medicine, found no significant difference between psilocybin and escitalopram, a widely used antidepressant sold under the brand name Lexapro™, in the treatment of depression.

A 2020 clinical trial at Johns Hopkins University's Center for Psychedelic & Consciousness Research, the leading psychedelic research institution in the US, suggests that psilocybin with therapy is efficacious in treating Major Depressive Disorder. Additional research at Johns Hopkins has demonstrated the therapeutic effects of psilocybin in people facing conditions such as addiction (smoking, alcohol, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression. Further studies at Johns Hopkins are currently underway to determine the effectiveness of psilocybin as a therapy for Alzheimer's disease, post-traumatic stress disorder, post-treatment Lyme disease syndrome, anorexia nervosa, and alcohol use in people with major depression.

Paul Rothman, M.D., Dean of the Johns Hopkins University School of Medicine, stated: "Johns Hopkins is deeply committed to exploring innovative treatments for our patients. Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential."

With accurate dosing a significant problem, and difficult to achieve with botanicals, pioneering companies such as Love Pharma, are developing new extracted products designed to deliver consistent dosing.

Joshua Maurice, COO, stated: "Considering the incredible advancement of psychedelics (most notably, psilocybin) in the health and wellness market, Love Pharma's excitement about partnering with a US based pharmaceutical company - developing the technology behind this muco-adhesive strip as a delivery system for psilocybin - is palpable. We recognize the need for discreet, consumer-friendly applications; and with its delivery of consistent dosing, this sublingual strip hits all the marks."

Founded in 2020, Love Pharma is focused on the Global Sexual Health, Wellness, and Psychedelics markets, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

The company is initially launching Bloom, a topical gel that increases blood circulation and sensitivity, with future hemp-infused versions, designed to further improve blood circulation and sensitivity, along with Auralief, a discreet cannabis-infused oral strip that expedites and enhances the desired effects of THC and CBD. The company has a number of other proven products in the pipeline to aid in mental and sexual health and wellness. The company is also actively seeking additional mergers and acquisitions to complement its strong portfolio of intellectual property.

For more information, please visit the company's website www.love-pharma.com, contact Zach Stadnyk, President and CEO, at 604-343-2977 or by email at investors@love-pharma.com.

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100692

News Provided by Newsfile via QuoteMedia

FDA Approves Merck's KEYTRUDA® as Adjuvant Treatment for Adult and Pediatric Patients With Stage IIB or IIC Melanoma Following Complete Resection

KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC Melanoma

KEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III Disease

Keep reading... Show less

Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada

 Merck (NYSE: MRK), known as MSD outside Canada and the United States announced today that it has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of COVID-19. This investigational medicine is being developed by Merck in collaboration with Ridgeback Biotherapeutics.

Keep reading... Show less

H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR  OTCQB: BETRF FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that Dr. Ahmad Doroudian will be participating in the H.C. Wainwright 2 nd Annual Psychedelics Conference. The event will be held virtually on Monday, December 6, 2021.

The theme of the conference is " Positioning for the Psychedelic Comeback in Mental Healthcare and Beyond ". This event will assemble all the key thought leaders and companies in the space to discuss this paradigm shift.

Keep reading... Show less

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE for Use in Infants and Children

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age. The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of April 1, 2022.

"VAXNEUVANCE has the potential to provide meaningful protection against invasive pneumococcal disease for children and infants by targeting pneumococcal strains, or serotypes, that contribute to substantial disease burden, including serotype 3, and broadening coverage to additional disease-causing serotypes, 22F and 33F, which are not included in the pneumococcal conjugate vaccine (PCV) currently available for this population," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "We look forward to working with the U.S. FDA as it reviews what would be the first new option in pediatric pneumococcal vaccination in over a decade."

Keep reading... Show less

Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided the following statement at the conclusion of the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) regarding the Emergency Use Authorization (EUA) application for molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 and/or hospitalization. The Advisory Committee voted 13-10 that the known and potential benefits of molnupiravir outweigh its known and potential risks for the treatment of mild to moderate COVID-19 in high risk adult patients who are within five days of symptom onset. The FDA is not bound by the committee's guidance but takes its advice into consideration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006127/en/

Keep reading... Show less

Merck Announces First-Quarter 2022 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company's common stock for the first quarter of 2022. Payment will be made on Jan. 7, 2022 to shareholders of record at the close of business on Dec. 15, 2021.

About Merck

Keep reading... Show less

Top News

Related News